Houston startup nonprofit partners with local initiative to bolster Black entrepreneurs

A new initiative between two Houston organizations is dedicating resources to Black entrepreneurs. Photo via houston.impacthub.net

Impact Hub Houston has partnered with the Black Marketing Initiative to offer a new training, mentoring, and networking program for local black entrepreneurs in honor of Black History Month.

Dubbed MarketBlack, the program will provide participants with 7 weeks of workshops and interactive training modules designed to help them create successful business plans and foster growth through practical lessons from educators and fellow entrepreneurs, according to a statement from Innovation Hub Houston.

The idea was born in June of 2020 when BMI conducted its Community Checkup campaign to assess the vitality of minority-owned small businesses in Houston amid the pandemic. The campaign surveyed 226 mostly Black-owned businesses, according to Impact Hub Houston's website. Nearly half of those surveyed reported that they needed business and marketing support.

The program will aim to provide participating entrepreneurs with the skills to keep their businesses alive through the remainder of the pandemic and beyond.

"The Black Marketing Initiative is not just about being Black — it is also about the belief that community can positively impact us all," says Action Jackson, a leader and organizer of MarketBlack. "Successful Black entrepreneurs are good for business. Good for community. Good for everybody."

The program is open to Houston-based small businesses that make less than $50,000 a year, are less than 5 years old, and are majority Black-owned. The owner must be at least 18 years old. Interested business owners can apply here.

According to ImpactHub, the majority of businesses that have participated thus far have not had a business plan and make less than $25,000 in annual revenue. Participants have ranged in age from 20 to 47, are split about evenly between male and female, and have all been Black with one participant also claiming American Indian or Alaskan Native Heritage.

Impact Hub Houston is sponsoring and raising funds for the program, as well as opening its network and community to participants. According to the nonprofit's website, a donation of $100 can support one entrepreneur through the program.

Houston-based Sankofa Research Institute is providing BMI with progress and outcomes to give the organization a snapshot of Houston's Black business community and determine the efficacy of the program.

Other partners and participants in MarketBlack include Action One Media, Marcus Bowers of Marcus Bowers TV and She's Happy Hair, Choose to Do Inc, Emergent Business Solutions, and South Union CDC of the Sunnyside Energy Project. These organizations and other local business owners act as panelists, instructors, and even financial partners to the participants.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted